Evolution of Phosphoinositide Lipid Kinases and Their Role in Drug Discovery
Author Information
Author(s): James R Brown, Kurt R Auger
Primary Institution: GlaxoSmithKline
Hypothesis
What are the evolutionary relationships of phosphoinositide lipid kinases (PIKs) across major eukaryotic groups and their implications for drug discovery?
Conclusion
The phylogenomic analysis of PIKs provides new insights into the evolution of second messenger signaling and suggests potential drug targets for various diseases.
Supporting Evidence
- PIKs are critical for second messenger signaling and cellular membrane remodeling.
- The study identifies four core eukaryotic PIKs and their evolutionary relationships.
- Mutated PIK3CA are known to be oncogenic and several inhibitors are in anti-cancer clinical trials.
- The analysis suggests that PIKs could be targeted for drug discovery in various diseases.
Takeaway
This study looks at how certain proteins help cells communicate and how understanding their evolution can help us find new medicines.
Methodology
The study involved phylogenetic analyses of phosphoinositide lipid kinases from various eukaryotic species using genomic data.
Limitations
The study may not cover all possible lipid kinase homologs and lacks data on some kinases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website